CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 41,554	$ 15,880
Cost of revenue:
Total cost of revenue	12,788	3,776
Gross profit	28,766	12,104
Operating expenses:
Research, development and clinical trials	5,871	7,534
Selling, general and administrative	24,984	13,939
Total operating expenses	30,855	21,473
Loss from operations	(2,089)	(9,369)
Other income (expense):
Interest expense	(1,091)	(960)
Other income (expense), net	555	(227)
Total other expense, net	(536)	(1,187)
Loss before income taxes	(2,625)	(10,556)
Provision for income taxes	(11)	(6)
Net loss	$ (2,636)	$ (10,562)
Net loss per share attributable to common stockholders, basic	$ (0.08)	$ (0.38)
Net loss per share attributable to common stockholders, diluted	$ (0.08)	$ (0.38)
Weighted average common shares outstanding, basic	32,260,267	27,950,330
Weighted average common shares outstanding, diluted	32,260,267	27,950,330
Net product revenue [Member]
Revenue:
Total revenue	$ 33,993	$ 14,939
Cost of revenue:
Total cost of revenue	7,306	3,378
Service Revenue [Member]
Revenue:
Total revenue	7,561	941
Cost of revenue:
Total cost of revenue	$ 5,482	$ 398